New software platform improves freeze drying process control
The LyoS 2.0 control system software is fully configurable and fully validatable for regulated pharmaceutical and biotechnology applications.
SP Scientific has launched LyoS 2.0 – a line-of-sight enabled lyophilizer control system able to control platforms from development to production units, making cycle transfer and scale-up much simpler.
The LyoS 2.0 control system delivers unmatched process control for all stages of the cycle, from freezing to primary and secondary drying. User definable process alarms protect the user's valuable product and automated system tests to ensure the lyophilizer is running optimally.
In addition, the control system is designed to control proprietary SP Scientific freeze drying technologies including ControLyo ice nucleation, SMART automatic cycle development and LyoFlux TDLAS continuous process monitoring.
Optional 21 CFR Part 11 compliance capabilities ensure that LyoS 2.0 control system software is both fully configurable and fully validatable for regulated pharmaceutical and biotechnology applications. SP Scientific offers testing protocols intended to support the processes that will be performed by the purchaser and/or end user, as well as onsite control system IQ/OQ validation support and a comprehensive factory-initiated software validation.
Designed for SP Scientific's research, development, and production lyophilizers, including the LyoCapsule, LyoStar, Genesis, Ultra and LyoConstellation. LyoS 2.0 and SP Line of Sight technologies can be upgraded on to certain other freeze dryers.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.